The relapse rate after allogeneic stem cell transplant (allo-HSCT) for leukemia varies significantly but often falls in the 20% to 60% range, with many studies showing rates around 30-50%, as relapse is the leading cause of treatment failure, especially for AML and ALL. Rates depend heavily on the patient's disease status (e.g., remission at transplant), disease risk, type of leukemia, donor match, and age, with higher risks for high-risk disease or transplants not done in complete remission.
Relapse of the original malignancy after SCT now remains the most frequent cause of treatment failure and mortality. Approximately 40–45% of recipients of HLA-identical siblings and approximately 35% of recipients of unrelated donor transplants will relapse with their original malignancy (Figure 1) [1].
People with ALL must be treated. Without treatment, survival is only a few months. With current treatment regimens, about 80%–90% of people with ALL will reach a complete remission (which means that leukemia cells cannot be seen in the bone marrow). About half of these people relapse.
For some people, there is a chance that their cancer can come back after a stem cell transplant. This is a particular risk if the disease was in an advanced stage or had already come back at the time of the transplant.
If you achieve remission with salvage chemotherapy, you may be able to have a stem cell transplant. This offers the best chance of a long-term cure, although unfortunately relapses after transplant can still happen.
The median survival after relapse was 4.5 months (95% CI, 4–5 months). The 1-year overall survival was 24% (95% CI, 20–26%), and the 5-year overall survival was 10% (95% CI, 8–12%). In 15 patients (6%) no treatment was attempted to obtain a second remission.
Let's talk about skin cancer. It is the most common secondary cancer after stem cell transplant and can include squamous cell cancer, basal cell carcinoma, as well as melanoma. The cumulative, that means the overall, incidence over a period of 20 years is about 6% for basal cell and 3% of squamous cell.
Life expectancy after a stem cell transplant varies. It depends on the condition, age, and health. Some patients live 20 years or more after the transplant.
Your doctor will need to do tests to find out if you've had a relapse or if something else is going on. You might have some of the same tests as when you were first diagnosed: Blood tests. These tests check the numbers of normal blood cells and leukemia cells in a sample of blood taken from your vein.
Stem cell transplants do not usually work against cancer directly. Instead, they restore your body's ability to produce new blood cells after treatment with the very high doses of chemotherapy and maybe other treatments, such as radiation therapy, that are used to destroy cancer cells.
10 Strategies for Preventing A Relapse
There isn't a cure for leukemia, but this doesn't mean some people don't achieve long-term remission. Being cured of leukemia means that the cancer's gone, it's not coming back and no more treatment is needed — but this is hard to know for sure with leukemia.
Genetic mutations (changes) cause acute lymphoblastic leukemia. Young children with ALL may have had gene changes that happened before they were born. Or you might inherit conditions that make you more likely to develop ALL. In adults, acute lymphoblastic leukemia is linked to some carcinogens, including tobacco.
What are the first signs that a blood stem cell transplant has been a success? After two to four weeks, an increase in the patient's white corpuscle count offers an initial indication that the new blood stem cells are doing their job and creating healthy blood cells.
Second allogeneic hematopoietic stem-cell transplantation (HSCT2) is a therapeutic option for patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) relapsing after a first transplant (HSCT1).
While acute lymphoblastic leukemia in children is more common than other types of cancer, it has high cure rates. Survival rates are lower in adults, but they are improving. The 5-year relative survival rate for ALL is 68.8%. The statistics further break down to 90% in children and 30-40% in adults.
If you've had graft failure or rejection, or for some people who have relapsed, your medical team might offer a second stem cell transplant. In some cases, you might use the same donor as your first transplant, but have the transplant with different chemotherapy drugs.
Relapsed acute lymphoblastic leukemia, or relapsed ALL, refers to the return of acute lymphoblastic leukemia (ALL) in patients who have already undergone treatment for the disease. Between 15 and 20 percent of children who are treated for ALL and achieve an initial complete remission will have the disease return.
You are in complete remission (CR) if:
If you've been coping with cancer or a blood disease, a stem cell transplant can be a new lease on life. It can mean hope for a cure or remission when other treatments haven't worked. But stem cell transplants come with demanding physical challenges and significant risks.
100 Days After Stem Cell or Bone Marrow Transplant
Reaching the 100-day mark after a stem cell or bone marrow transplant is a major milestone. It means that engraftment is well underway and the risk for serious complications, including infection and GVHD, is subsiding.
Despite improvements, stem cell transplantation is associated with increased overall mortality and decreased life expectancy. Causes of death after an allogeneic stem cell transplant (a transplant using cells from a donor) include relapse, infections, secondary cancers, and heart disease.
Incurable cancers are those that current treatments cannot completely eliminate, often because they are advanced (spread) or have returned after initial treatment, but they are not necessarily untreatable; treatments like chemo, radiation, and new targeted therapies aim to control the disease, slow growth, relieve symptoms, and improve quality of life. Common examples of cancers often considered incurable include pancreatic, liver, brain, esophageal, and certain advanced lung cancers, but research continuously offers new hope, with many patients living longer with ongoing management.
A blood or marrow transplant (BMT), also known as a bone marrow or blood stem cell transplant, can treat AML, including in older patients. It replaces unhealthy blood stem cells with healthy ones from a donor. For some, it can be a cure for their disease.
Common treatments for graft failure
A second transplant may use: Cells from the same donor. Cells from a different donor. A different cord blood unit or an adult donor if you had a cord blood unit.